NECTIN4 and neoplasm: TROP-2 and nectin-4 were initially added as the tumor targets for sacituzumab govitecan and enfortumab vedotin, meanwhile, it extended further to include HER2 as target for trastuzumab deruxtecan for better therapeutic index (20).